Supernus Pharmaceuticals

Last Updated:



quotes and stock data delayed 15 minutes



Burn Rate (Qtr)


Company Profile

We are a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our extensive expertise in product development has been built over the past 25 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, in late 2005, as Supernus Pharmaceuticals Inc. We market our products in the United States through our own specialty sales force and seek strategic collaborations with other pharmaceutical companies to license our products outside the United States.

We market Trokendi XR® (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, Oxtellar XR® (extended-release oxcarbazepine) for the treatment of epilepsy, Apokyn® (apomorphine hydrochloride injection) for the acute treatment of hypomobility in advanced Parkinson’s disease (PD), Myobloc® (rimabotulinumtoxinB) for the treatment of cervical dystonia and treatment of chronic sialorrhea in adults, and Xadago® (safinamide) as an adjunctive treatment to levodopa/carbidopa in PD patients with hypomobility.

We are also developing several product candidates to address large market opportunities in the CNS market, including SPN-812 for the treatment of ADHD, apomorphine infusion pump for hypomobility in PD, SPN-820 (NV-5138) for treatment-resistant depression, and SPN-817 for the treatment of epilepsy.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

Oxtellar XR® (oxcarbazepine)


Quarterly Sales (Approved)

February 12, 2021 (Est)

Trokendi XR® (topiramate)

Prophylaxis of migraine

Quarterly Sales (Approved)

February 12, 2021 (Est)

APOKYN® (apomorphine hydrochloride injection)

Advanced Parkinson’s disease (PD)

Quarterly Sales (Approved)

February 12, 2021 (Est)

XADAGO (safinamide)

Parkinson's disease

Quarterly Sales (Approved)

February 12, 2021 (Est)

MYOBLOC® (rimabotulinumtoxinB)

Cervical Dystonia Sialorrhea

Quarterly Sales (Approved)

February 12, 2021 (Est)

Trokendi XR® (topiramate)


Quarterly Sales (Approved)

February 12, 2021 (Est)

SPN-812 (viloxazine hydrochloride)

Attention deficit hyperactivity disorder (ADHD)

NDA Resubmission



Parkinson’s Disease

NDA Acceptance

Q4 2021 (Est)

Recent Posts

See what the community is saying - click to see full post

SUPN - Refusal to File (RTF) letter from the FDA regarding its NDA for SPN-830 for the treatment of Parkinson’

SUPN - Complete Response Letter (CRL) regarding the New Drug Application (NDA) for SPN-812 for the treatment o

SUPN - Supernus Announces Third Quarter 2020 Financial Results

*Disclaimer: Information provided on and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon